News und Analysen
Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia Gravis
Regulatory News:
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that
Charles River and Valo Health Announce Strategic Partnership to Provide Clients with Access to AI-Enabled Drug Discovery Solutions
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, LLC (“Valo”), the technology company using human-centric data and computation powered by artificial intelligence (AI) to
QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year results of 2021 on Tuesday, February 8
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced that the European Commission has approved Tavneos® in combination with a rituximab or cyclophosphamide regimen
QIAGEN Launches QIAwave Portfolio of Environmentally Friendly Products
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its new QIAwave product line by launching three nucleic acid extraction kits that use fewer components and produce less waste
QIAGEN führt mit QIAwave umweltfreundliche Produktlinie ein
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Einführung seiner neuen Produktlinie QIAwave und der ersten drei QIAwave Nukleinsäure-Extraktionskits bekannt. Diese neuen Kits
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and PersonGen BioTherapeutics, a Chinese
PINC AI™ Launches INsights, an Enhanced Technology Offering for Customized, On-Demand Healthcare Analytics
PINC AI™, the technology and services platform of Premier, Inc (NASDAQ: PINC), today launched INsights, an enhanced self-service healthcare solution for the creation of customized, on-demand
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
DGAP-News: Evotec und Lilly gehen Zusammenarbeit zur Erforschung von Wirkstoffen im Bereich Stoffwechselerkrankungen ein
DGAP-News: Evotec and Lilly enter into drug discovery collaboration in metabolic diseases
DGAP-News: Biotest AG: Biotest combats climate change through CO2-neutral production
DGAP-News: Biotest AG: Biotest bekämpft Klimawandel durch CO2-neutrale Produktion
Waters beschleunigt quantitative Massenspektrometrie mit neuer Anwendung auf der Informatikplattform waters_connect
ie Waters Corporation (NYSE:WAT) gab heute bekannt, dass sie ihre Informatik-Softwareplattform waters_connect™ erweitert, um Kunden bei der Analyse von Nahrungsmittel- und Umweltproben mit
Sensorion Updates on SENS-401 Phase 2 trial in Sudden Sensorineural Hearing Loss
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for
DGAP-Adhoc: RHÖN-KLINIKUM AG einigt sich mit dem Land Hessen über Absichtserklärung zu Investitionsfördermitteln
DGAP-Adhoc: RHÖN-KLINIKUM AG has reached an agreement with the State of Hesse on letter of intent on public investment subsidies
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
HAEMATO vertreibt PCR Point-of-Care Geräte zur wirkungsvollen Eindämmung des Corona-Pandemiegeschehens
Premier Inc.’s Contigo Health Expands Provider-Sponsored Health Plan Offerings Through New Partnership With OhioHealthy
Contigo Health LLC, a subsidiary of Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced a new partnership with OhioHealthy Plans, LLC
Agilent to Webcast First-Quarter Fiscal Year 2022 Financial Results Presentation
Agilent Technologies Inc. (NYSE: A) will release first-quarter fiscal year 2022 financial results after the stock market closes on Tuesday, Feb. 22. The company will host a live webcast of its
Simulations Plus Enters New Collaboration with Leading Animal Health Company
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced a new
Lysogene Announces Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a gene therapy platform company targeting central nervous system (CNS) diseases, today announced the termination of its license